Adams Gareth J, Greene Jennifer, Vick G Wesley, Harrist Ronald, Kimball Kay T, Karmonik Christof, Ballantyne Christie M, Insull William, Morrisett Joel D
Structural and Computational Biology and Molecular Biophysics Program, Baylor College of Medicine, Houston, TX, USA.
Magn Reson Imaging. 2004 Nov;22(9):1249-58. doi: 10.1016/j.mri.2004.08.020.
Magnetic resonance imaging (MRI) can accurately and reproducibly measure the volume of atherosclerotic plaque in human carotid arteries. Atherosclerotic plaques may either progress or regress over time, depending on individual risk factors and treatment regimens. This study was designed to determine if regression or progression of human carotid atherosclerosis in patients receiving statin therapy over 24 months can be detected by high-resolution MRI.
In 11 subjects who had undergone unilateral carotid endarterectomy and were on statin therapy, volumes for total carotid artery, concentric wall (normal wall), eccentric wall (plaque), and lumen were quantified at 0, 16 and 24 months using a 1.5-T human imager equipped with 6-cm phased array coils.
The interobserver mean coefficient of variation (CV) was lowest for the lumen volume (3.1%) and highest for the plaque volume (9.8%). The interscan mean CV was lowest for the total artery volume (3.2%) and highest for the plaque volume (9.9%). As much as 26% regression and 35% progression were observed in individual subject's carotid artery eccentric wall (plaque) volumes over time. Mean eccentric wall volume increased 5% by 16 months and 8% by 24 months. Mean total wall volume increased slightly at both 16 and 24 months (+1.2% and +1.8%).
High-resolution MRI provides a noninvasive reproducible method of tracking changes in carotid atherosclerosis. This pilot study detected changes in individual subjects at both 16 and 24 months. MRI tracking of changes in atherosclerotic plaques should prove useful in assessing vascular disease risk and monitoring the efficacy of interventions designed to induce regression or retard progression.
磁共振成像(MRI)能够准确且可重复地测量人体颈动脉粥样硬化斑块的体积。随着时间推移,动脉粥样硬化斑块可能进展或消退,这取决于个体风险因素和治疗方案。本研究旨在确定高分辨率MRI能否检测接受他汀类药物治疗24个月的患者颈动脉粥样硬化的消退或进展情况。
选取11例接受过单侧颈动脉内膜切除术且正在接受他汀类药物治疗的受试者,使用配备6厘米相控阵线圈的1.5-T人体成像仪,分别在0、16和24个月时对颈动脉总体积、同心壁(正常壁)、偏心壁(斑块)和管腔的体积进行量化。
观察者间平均变异系数(CV)在管腔体积方面最低(3.1%),在斑块体积方面最高(9.8%)。扫描间平均CV在总动脉体积方面最低(3.2%),在斑块体积方面最高(9.9%)。随着时间推移,个体受试者颈动脉偏心壁(斑块)体积出现高达26%的消退和35%的进展。平均偏心壁体积在16个月时增加5%,在24个月时增加8%。平均总壁体积在16个月和24个月时均略有增加(分别为+1.2%和+1.8%)。
高分辨率MRI提供了一种跟踪颈动脉粥样硬化变化的非侵入性可重复方法。这项初步研究在16个月和24个月时均检测到了个体受试者的变化。MRI跟踪动脉粥样硬化斑块的变化在评估血管疾病风险和监测旨在诱导消退或延缓进展的干预措施的疗效方面应会被证明是有用的。